Lobular Neoplasia in Breast Core Needle Biopsy Specimens Is Associated With a Low Risk of Ductal Carcinoma In Situ or Invasive Carcinoma on Subsequent Excision

2008 ◽  
Vol 2008 ◽  
pp. 37-39
Author(s):  
G. Cai
2018 ◽  
Vol 142 (9) ◽  
pp. 1120-1126 ◽  
Author(s):  
Mirna B. Podoll ◽  
Emily S. Reisenbichler ◽  
Lania Roland ◽  
Andrew Bruner ◽  
Sarah Mizuguchi ◽  
...  

Context.— Ductal carcinoma in situ (DCIS) represents 20% of screen-detected breast cancers. The likelihood that certain types of DCIS are slow growing and may never progress to invasion suggests that our current standards of treating DCIS could result in overtreatment. The LORIS (LOw RISk DCIS) and LORD (LOw Risk DCIS) trials address these concerns by randomizing patients with low-risk DCIS to either active surveillance or conventional treatment. Objective.— To determine the upgrade rate of DCIS diagnosed on core needle biopsy to invasive carcinoma at surgery and to evaluate the safety of managing low-risk DCIS with surveillance alone, by characterizing the pathologic and clinical features of upgraded cases and applying criteria of the LORD and LORIS trials to these cases. Design.— A 10-year retrospective analysis of DCIS on core needle biopsy with subsequent surgery. Results.— We identified 1271 cases of DCIS on core needle biopsy: 200 (16%) low grade, 649 (51%) intermediate grade, and 422 (33%) high grade. Of the 1271 cases, we found an 8% upgrade rate to invasive carcinoma (n = 105). Nineteen of the 105 upgraded cases (18%) had positive lymph nodes. Low-grade DCIS was least likely to upgrade to invasion, comprising 10% (10 of 105) of upgraded cases. Three of the 105 upgraded cases (3%) met criteria for the LORD trial, and all were low-grade DCIS on core needle biopsy with favorable biology on follow-up. Conclusions.— There is a clear risk of upgrade to invasion on follow-up excision; however, applying strict criteria of the LORD trial effectively decreases the likelihood of a missed invasive component or missed aggressive pathologic features.


Breast Care ◽  
2019 ◽  
Vol 15 (3) ◽  
pp. 260-264
Author(s):  
Robbert J.H. van Leeuwen ◽  
Birgitta Kortmann ◽  
Herman Rijna

Introduction: In some hospitals it is still common practice to carry out a sentinel node biopsy (SNB) if ductal carcinoma in situ (DCIS) is determined in preoperative staging, although this is against international guidelines. The reason for this is because an infiltrative component can be demonstrated frequently in the final pathohistological examination. In this study, we wanted to investigate possible predictors for infiltrative growth, to select patients to do an SNB or to omit it. Material and Methods: All patients with DCIS in the core needle biopsy (CNB), who were treated with surgery including an SNB, were included in a prospective data registry. Patient characteristics were collected through physical examination, mammography and ultrasonography. All characteristics of the DCIS were noted. After surgery, the pathological results were collected. Results: From the 287 patients, 39 (13.6%) had an infiltrative component in the definitive pathological examination despite only DCIS in preoperative CNB. In total, there were only 14 (4.9%) positive SNBs, of which 11 patients had infiltrative growth in the breast tumor and 3 (1.2% of patients with DCIS alone in the final pathology) did not. In addition, characteristics of the CNB, including microcalcifications and comedonecrosis, did not show a statistically significant higher risk for infiltration. Discussion: Considering the low rates of positive SNBs in our population, we think that an SNB should not be performed in advance when DCIS is diagnosed, because if infiltrative growth is found in the final biopsy, an SNB could always be performed afterwards. Only if an SNB cannot be performed afterwards is an SNB indicated.


The Breast ◽  
2004 ◽  
Vol 13 (6) ◽  
pp. 461-467 ◽  
Author(s):  
M.A.J. de Roos ◽  
R.M. Pijnappel ◽  
A.D. Groote ◽  
J. de Vries ◽  
W.J. Post ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document